Comparing Amylyx Pharmaceuticals (NASDAQ:AMLX) & Mannatech (NASDAQ:MTEX)

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Profitability

This table compares Amylyx Pharmaceuticals and Mannatech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-68.95%	-61.52%
Mannatech	-1.50%	-22.75%	-4.75%

Risk and Volatility

Amylyx Pharmaceuticals has a beta of -0.34, suggesting that its stock price is 134% less volatile than the S&P 500. Comparatively, Mannatech has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Insider & Institutional Ownership

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.0% of Mannatech shares are owned by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 41.5% of Mannatech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Amylyx Pharmaceuticals and Mannatech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1	2	9	2	2.86
Mannatech	1	0	0	0	1.00

Amylyx Pharmaceuticals currently has a consensus target price of $17.25, suggesting a potential upside of 41.51%. Given Amylyx Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe Amylyx Pharmaceuticals is more favorable than Mannatech.

Valuation and Earnings

This table compares Amylyx Pharmaceuticals and Mannatech”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37 million	15.32	-$301.74 million	($1.80)	-6.77
Mannatech	$117.87 million	0.14	$2.49 million	($0.86)	-10.36

Mannatech has higher revenue and earnings than Amylyx Pharmaceuticals. Mannatech is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Amylyx Pharmaceuticals beats Mannatech on 8 of the 15 factors compared between the two stocks.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

About Mannatech

Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.